Foghorn Therapeutics (FHTX) Non Operating Income (2019 - 2026)

Foghorn Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 58.37% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $9.7 million (down 42.67% YoY), while the FY2025 annual figure was $12.1 million, down 24.63% from the prior year.
• Non Operating Income for Q1 2026 stood at $1.7 million, down from $2.2 million in the prior quarter.
• The five-year high for Non Operating Income was $4.7 million in Q3 2024, with the low at $890000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $3.2 million (2024), against an average of $3.0 million.
• The sharpest annual moves came in 2022 and 2026: Non Operating Income surged 1275.69% in 2022, then plunged 58.37% in 2026.
• Foghorn Therapeutics' Non Operating Income stood at $3.0 million in 2022, then gained by 11.27% to $3.3 million in 2023, then soared by 34.87% to $4.5 million in 2024, then sank by 50.82% to $2.2 million in 2025, then retreated by 23.31% to $1.7 million in 2026.
• Business Quant data shows FHTX's Non Operating Income at $1.7 million in Q1 2026, $2.2 million in Q4 2025, and $2.7 million in Q3 2025.